NUVA · Nuvasive Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $317.79M | $307.71M | - | $295.28M | $310.45M | $290.76M | - | $270.84M | $294.83M | $271.25M |
| Cost of Revenue | $89.47M | $86.37M | - | $80.87M | $85.76M | $79.10M | - | $88.65M | $78.28M | $71.81M |
| Gross Profit | $228.31M | $221.34M | - | $214.41M | $224.69M | $211.66M | - | $182.18M | $216.55M | $199.44M |
| R&D | $28.65M | $24.57M | - | $23.67M | $25.91M | $23.36M | - | $23.41M | $21.76M | $22.22M |
| SG&A | $163.86M | $176.19M | - | $154.00M | $160.70M | $160.28M | - | $146.06M | $157.40M | $145.95M |
| Total Operating Expenses | $210.35M | $214.18M | - | $192.64M | $191.62M | $199.73M | - | $188.82M | $205.80M | $187.10M |
| D&A | - | $33.47M | - | - | - | $36.80M | - | - | - | $36.43M |
| Operating Income | $12.49M | $180.0K | - | ($2.82M) | ($700.0K) | $23.84M | - | ($24.01M) | $7.64M | ($8.13M) |
| Interest Expense | $6.01M | $4.38M | - | $4.35M | $4.35M | $4.38M | - | $4.32M | $4.39M | $8.03M |
| Income Tax | $5.12M | $1.19M | - | ($839.0K) | $193.0K | $4.64M | - | ($2.37M) | $5.84M | ($620.0K) |
| Net Income | $7.36M | ($1.01M) | - | ($1.98M) | ($893.0K) | $19.20M | - | ($21.64M) | $1.80M | ($7.51M) |
| EPS - Basic | $0.14 | ($0.02) | - | ($0.04) | ($0.02) | $0.37 | - | ($0.42) | $0.03 | ($0.15) |
| EPS - Diluted | $0.14 | ($0.02) | - | ($0.04) | ($0.02) | $0.35 | - | ($0.42) | $0.03 | ($0.15) |
Balance Sheet
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $80.72M | $181.20M | $248.66M | $237.50M | $225.99M | $205.31M | $246.09M | $234.58M | $204.14M | $233.86M |
| Accounts Receivable | $267.11M | $250.02M | $249.37M | $235.58M | $233.57M | $231.43M | $214.40M | $199.37M | $216.91M | $205.03M |
| Inventory | $350.81M | $345.94M | $338.60M | $341.00M | $331.71M | $324.40M | $315.85M | $311.41M | $319.73M | $315.75M |
| Accounts Payable | - | - | $20.32M | - | - | - | $16.19M | - | - | - |
| Current Assets | $728.25M | $806.36M | $865.21M | $843.23M | $823.31M | $792.21M | $802.42M | $770.36M | $765.75M | $781.56M |
| Total Assets | $2.09B | $2.17B | $2.22B | $2.17B | $2.17B | $2.16B | $2.15B | $2.13B | $2.15B | $2.16B |
| Current Liabilities | $582.58M | $674.80M | $716.05M | $697.40M | $701.36M | $248.73M | $200.89M | $195.36M | $193.73M | $224.88M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $892.54M | $873.68M | $868.89M | $824.20M | $795.21M | $811.92M | $795.21M | $824.20M | $840.90M | $835.39M |
| Retained Earnings | $92.47M | $85.10M | $86.11M | $62.04M | $64.02M | $64.91M | $45.71M | $82.44M | $104.08M | $102.28M |
Cash Flow
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | $1.97M | - | - | - | $6.54M | - | - | - | $31.64M |
| Investing Cash Flow | - | ($35.15M) | - | - | - | ($34.17M) | - | - | - | ($2.65M) |
| Financing Cash Flow | - | ($34.90M) | - | - | - | ($12.71M) | - | - | - | ($649.83M) |
| CapEx | - | $35.15M | - | - | - | $33.22M | - | - | - | $25.07M |
| Free Cash Flow | - | ($33.18M) | - | - | - | ($26.68M) | - | - | - | $6.57M |
Ratios
| Metric | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 71.8% | 71.9% | - | 72.6% | 72.4% | 72.8% | - | 67.3% | 73.4% | 73.5% |
| Operating margin | 3.9% | 0.1% | - | -1.0% | -0.2% | 8.2% | - | -8.9% | 2.6% | -3.0% |
| EBITDA margin | - | 10.9% | - | - | - | 20.9% | - | - | - | 10.4% |
| Net margin | 2.3% | -0.3% | - | -0.7% | -0.3% | 6.6% | - | -8.0% | 0.6% | -2.8% |
| Free cash flow margin | - | -10.8% | - | - | - | -9.2% | - | - | - | 2.4% |
| FCF / Net income | - | 32.75 | - | - | - | -1.39 | - | - | - | -0.87 |
| R&D / Revenue | 9.0% | 8.0% | - | 8.0% | 8.3% | 8.0% | - | 8.6% | 7.4% | 8.2% |
| SG&A / Revenue | 51.6% | 57.3% | - | 52.2% | 51.8% | 55.1% | - | 53.9% | 53.4% | 53.8% |
| Effective tax rate | 41.0% | 662.8% | - | - | - | 19.5% | - | - | 76.4% | - |
| Return on assets | 0.4% | -0.0% | - | -0.1% | -0.0% | 0.9% | - | -1.0% | 0.1% | -0.3% |
| Return on equity | 0.8% | -0.1% | - | -0.2% | -0.1% | 2.4% | - | -2.6% | 0.2% | -0.9% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.25 | 1.19 | 1.21 | 1.21 | 1.17 | 3.19 | 3.99 | 3.94 | 3.95 | 3.48 |
| Quick ratio | 0.65 | 0.68 | 0.74 | 0.72 | 0.70 | 1.88 | 2.42 | 2.35 | 2.30 | 2.07 |
| Cash ratio | 0.14 | 0.27 | 0.35 | 0.34 | 0.32 | 0.83 | 1.22 | 1.20 | 1.05 | 1.04 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 2.1x | 0.0x | - | -0.6x | -0.2x | 5.4x | - | -5.6x | 1.7x | -1.0x |
| Equity multiplier | 2.34 | 2.48 | 2.56 | 2.64 | 2.73 | 2.66 | 2.71 | 2.59 | 2.55 | 2.59 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.15 | 0.14 | - | 0.14 | 0.14 | 0.13 | - | 0.13 | 0.14 | 0.13 |
| Inventory turnover | 0.26 | 0.25 | - | 0.24 | 0.26 | 0.24 | - | 0.28 | 0.24 | 0.23 |
| Days sales outstanding | 307d | 297d | - | 291d | 275d | 291d | - | 269d | 269d | 276d |
| Days inventory outstanding | 1431d | 1462d | - | 1539d | 1412d | 1497d | - | 1282d | 1491d | 1605d |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 2.4% | 5.8% | - | 9.0% | 5.3% | 7.2% | - | -8.3% | 44.8% | 4.4% |
| Revenue CAGR (3y) | 16.0% | 5.8% | - | 0.5% | 2.1% | 1.9% | - | -0.1% | 4.4% | 2.9% |
| Revenue CAGR (5y) | 4.1% | 4.3% | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 1.6% | 4.6% | - | 17.7% | 3.8% | 6.1% | - | -13.5% | 75.9% | 6.1% |
| Operating income growth (YoY) | - | -99.2% | - | 88.3% | - | - | - | - | - | - |
| Net income growth (YoY) | - | - | - | 90.9% | - | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | 90.5% | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | 24.8% | - | - | -48.5% | - |
| EPS CAGR (5y) | -8.6% | - | - | - | - | 9.7% | - | - | -44.5% | - |
| FCF growth (YoY) | - | -24.3% | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | -30.0% |
| Book value growth (YoY) | 12.2% | 7.6% | 9.3% | 0.0% | -5.4% | -2.8% | -13.5% | -8.4% | -6.0% | -5.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$2.28B totalProduct$1.03B · 45.4%
Spinal Hardware$856.56M · 37.6%
Surgical Support$282.43M · 12.4%
Service$104.38M · 4.6%
Geographic
$1.14B totalUS$876.61M · 77.0%
Non Us$262.37M · 23.0%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing NUVASIVE INC against the 5 most active filers in the same SIC group.